List view / Grid view
Gilead's complaint alleges five contract breaches by the US Centers for Disease Control and Prevention (CDC) and seeks a declaration of contract breach and damages.
According to the European Patent Office (EPO), in 2019 the number of patents filed in the pharmaceutical and biotechnology sectors rose for a third consecutive year.
Arguments filed in opposition to a patent for foundation CRISPR-Cas9 intellectual property have been rejected by the European Patents Office.
New research has suggested that the expiration of biologics patents will be the factor that positively impacts US pharma the most this year.
Following 250 US drug price increases in 2020 already, this article explores why costs are rising, what changes could ensure brand reputations remain intact and what manufacturers can do to ensure they get their share.
Inflazome has announced that the US and EU will grant patents to their NLRP3 inflammasome inhibiting compounds.
A US appeals court has upheld a ruling that threw out a $2.54 billion jury verdict Merck won against Gilead over hepatitis C treatments.
China has expanded a pilot drug bulk-buying programme to almost the entire country which is adding pressure on pharma companies.
Mylan NV's generic version Eli Lilly and Co’s lung cancer drug, Alimta, has been given tentative approval by the FDA.
Mahfoozur Rahman and Sarwar Beg explain why we need to change tack from traditional formulation-driven development to a target-based approach in order to increase success with anticancer nanomedicine in the clinic.
Antibody drug conjugates are presently recognised as a potent class of targeted anticancer therapies which will result in growth in the market.
A US district court has invalidated Amgen's patent claims for antibodies targeting PCSK9.
Sanofi has won the latest appeal for the patent of its top oncology product, Jevtana (cabazitaxel).
The US District Court has decided in favour of Amgen’s Enbrel, ruling over Sandoz’s Erelzi in a patent conflict.
The US District Court has ruled in favour of Eli Lilly in the Alimta patent lawsuit against Dr. Reddy's Laboratories and Hospira, Inc.
